ABSTRACT
Objective : The economic aspect of pharmaceuticals is becoming a major issue of health care financing in Japan due to the high total volume of drug consumption. To consider the feasibility and usefulness of pharmacoeconomic (PE) studies in health policy making, we aimed to conduct a review of PE studies published in Japan.<BR>Methods : We collected original published PE studies conducted in Japan from 1985 to 1995, by retrieving through computer databases such as MEDLINE and JMEDICINE, as well as other methods. We then reviewed the papers according to a checklist developed by Drummond et al.<BR>Results : Fourteen articles were found to satisfy the inclusion criteria. The overall checklist compliance rate were 45.8%. All of the PE studies were based on randomized clinical trial. Most of the studies lacked some important elements of PE analysis, such as the identification of all important and relevant costs and consequences (14.3%) and the presentation of all issues of concern (7.1%). Furthermore, most models and assumptions used in the studies were considered by us to be unreliable and inappropriate.<BR>Discussion : The quality of PE studies conducted in Japan was not considered by us to be satisfactory and our analysis identified areas for improvement. Further improvement in this field is urgently needed and may be achieved through PE guideline development and the training of specialists.